Payment overview · 2025
General Payments
$116.66
1 reported records · 1 companies
Healthcare provider profile · identity verified
Brian A Deprest, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1184689861
Verified facts
What the public records show
CMS Open Payments records show Brian A Deprest, M.D. received $116.66 in general payments during 2025 across 1 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $116.66 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $116.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $116.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 627 | 194 |
| Gabapentin | Gabapentin | 400 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 367 | 109 |
| Omeprazole | Omeprazole | 338 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 62 |
| Metformin Hcl | Metformin Hcl | 205 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 197 | 39 |
| Lisinopril | Lisinopril | 195 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 52 |
| Sertraline Hcl | Sertraline Hcl | 163 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 46 |
| Metformin Hcl Er | Metformin Hcl | 154 | 52 |
| Furosemide | Furosemide | 148 | 52 |
| Potassium Chloride | Potassium Chloride | 148 | 52 |
| Famotidine | Famotidine | 146 | 37 |
| Carvedilol | Carvedilol | 137 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 48 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 135 | 40 |
| Eliquis | Apixaban | 135 | 26 |
| Ozempic | Semaglutide | 135 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 33 |
| Baclofen | Baclofen | 133 | 34 |
| Losartan Potassium | Losartan Potassium | 127 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 33 |
| Mirtazapine | Mirtazapine | 108 | 24 |
| Ramipril | Ramipril | 106 | 33 |
| Montelukast Sodium | Montelukast Sodium | 105 | 33 |
| Glimepiride | Glimepiride | 103 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 34 |
| Allopurinol | Allopurinol | 94 | 29 |
| Alprazolam | Alprazolam | 93 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 30 |
| Trazodone Hcl | Trazodone Hcl | 89 | 28 |
| Alendronate Sodium | Alendronate Sodium | 86 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 39 |
| Tramadol Hcl | Tramadol Hcl | 79 | 18 |
| Jardiance | Empagliflozin | 76 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 14 |
| Simvastatin | Simvastatin | 69 | 24 |
| Promethazine Hcl | Promethazine Hcl | 65 | 11 |
| Celecoxib | Celecoxib | 63 | 26 |
| Meloxicam | Meloxicam | 61 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 21 |
| Ezetimibe | Ezetimibe | 59 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 38 |
| Spironolactone | Spironolactone | 55 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 17 |
| Pregabalin | Pregabalin | 53 | 12 |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Prednisone | Prednisone | 50 | 33 |
| Fluconazole | Fluconazole | 49 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 18 |
| Naproxen | Naproxen | 49 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 45 | 12 |
| Glipizide | Glipizide | 42 | 15 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Bumetanide | Bumetanide | 40 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 12 |
| Methylprednisolone | Methylprednisolone | 39 | 29 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 39 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 11 |
| Atenolol | Atenolol | 37 | 15 |
| Ibuprofen | Ibuprofen | 37 | 16 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 21 |
| Azithromycin | Azithromycin | 31 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | 11 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 26 | suppressed |
| Tivicay | Dolutegravir Sodium | 26 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | 11 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $116.66 · 1 records | E.R. Squibb & Sons, L.L.C. | CAMZYOS | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error